key: cord-0775628-6i99eosa
authors: Long, Qiong; Yang, Ying; Yang, Mengli; Bai, Hongmei; Sun, Wengjia; Yang, Xu; Huang, Weiwei; Li, Duo; Ma, Yanbing
title: Recombinant VLPs empower RBM peptides showing no immunogenicity in native SARS-COV-2 protein to elicit a robust neutralizing antibody response
date: 2022-01-30
journal: Nanomedicine
DOI: 10.1016/j.nano.2022.102527
sha: e7c9274fd64d3eaa4d03de08d762adb78c20edd2
doc_id: 775628
cord_uid: 6i99eosa

New SARS-COV-2 vaccine strategies are still urgently needed, especially for emerging virus mutations and variants. In this study, we focused on analyzing the antigenicity and vaccine potency of linear peptide epitopes located in receptor binding motif (RBM) of spike (S) protein. Nine 12 to 16-mer overlapping peptides (P1-P9) were synthesized chemically and coupled to carrier protein KLH for the immunization in mice. Four of identified peptides were further engineered to present on the surface of recombinant Hepatitis B core antigen (HBcAg) virus-like particles (VLPs) respectively. Antisera obtained from VLPs -immunized mice demonstrated strong reactivity and affinity to S1 protein or inactivated virus and neutralizing activity against virus infection in vitro. This study indicates that recombinant VLPs empower peptides which display underprivileged antigenicity in native protein to elicit high levels of neutralizing antibody, providing potential epitope candidates and an effective delivery strategy for the development of a multi-epitope vaccine.

preventing COVID-19 illness, including sever disease (7) .

As SARS-CoV-2 infection is new to humankind and the nature of protective immune responses is still not fully understood, it is unclear which vaccine strategies will be more efficient, persistently protective, and safer. The COVID-19 outbreak occurred repeatedly in many places worldwide, and virus (10, 11) . However, recent studies indicated that the protective efficacy of current vaccines reduced in response to SARS-CoV-2 variants (13) . Omicron variant was reported to have 32 mutations in spike protein, which may produce evasion and significantly limit the neutralization activity of vaccine-induced antibody and increase the risk of reinfections (14) . An in vitro finding using authentic SARS-CoV-2 variants indicated that the neutralization efficacy of vaccine-elicited sera against Omicron was severely reduced as compared to the currently circulating Delta variant (13) . Therefore, there are possibility that the emerging virus mutations and variations may pose a challenge to current vaccines and vaccination strategies (15, 16) . New and various vaccine platforms and strategies are still urgently needed to be explored and evaluated. It was listed that more than 300 vaccines based on various platform, antigen formulation and delivery strategy, SARS-CoV-2 invades target cells using human Angiotensin-converting enzyme 2 (ACE2) as a receptor (18, 19) . It is believed that the receptor-binding domain (RBD) and NTD of SARS-CoV-2 S protein play key roles in the binding of virus to ACE2, and the blockage of the binding is a major mechanism causing SARS-COV-2 neutralization (20) (21) (22) . Peptide-based vaccine strategy provides noteworthy benefits in vaccine design and preparation with the development of bioinformatics, synthetic technology and reverse genetics. The distinct virtues of peptide-based vaccine include: easy to screen, simple and convenient antigen source, low antigen complexity, flexible vaccine formulation, economical and rapid, specific immune target, and can be produced without using the pathogen itself (23, 24) . It may elicit a more concentrated immune response than a protein, multiple components, or the whole constitution of a pathogen, and thus is capable of focusing on the most conserved epitopes and those that represent the neutralizing and susceptible sites of the virus (25) (26) (27) .

Computer-based immunoinformatics and structural biology using resolved 3-dimensional (3D)

structures have been widely used to predict the antigenic T cell and B cell epitopes for the SARS- (31) . In this study, we focused on identifying neutralizing linear B cell epitopes in receptor binding motif (RBM) of SARS-CoV-2 spike (S) protein，which is directly involved in the interactive interface between SARS-CoV-2 and ACE2 ( Figure 1 ). We demonstrated that recombinant VLPs empowered peptides to elicit high levels of neutralizing antibody. Our study provides potential epitope candidates and delivery strategy for the development of a multi-epitope based SARS-COV-2 vaccine; In addition, it may also indicate a possible reinforcement strategy to current vaccines through highlighting neutralizing epitopes which are underprivilege for antigenicity presentation in native S protein. 

Totally 9 overlapping peptides (P1-P9) covering the whole length of RBM, as shown in Figure 1 

The recombinant plasmids encoding a chimeric protein with antigenic peptides inserted into the immunodominant epitope of hepatitis B core antigen (HBcAg) was constructed as previously reported. Briefly, the two strand fragment of oligonucleotides with BamH I and EcoR I cohesive ends, which encodes the antigenic peptides, were prepared by annealing synthetic two Polydispersity index (PDI) of the VLPs were measured in triplicates using a particle size analyzer (Nano ZS, Malvern Instruments, UK). for a total of three times. For immunization with KLH-peptide/Alum, 160 μg protein with 2 mg Alum per mouse was given for primary immunization and a dose of 80 μg protein was used for the following two booster immunizations. For an enhanced immunization procedure, complete and incomplete Freund's adjuvants were used to replace Alum, and 320 μg, 160 μg and 160 μg of antigen were given respectively for three immunizations. For immunization with HBcAg-peptide VLPs, 50 μg of protein with 2 mg Alum was inoculated into mice. The serum samples were collected at one week after each immunization, and splenocytes were isolated for analyzing peptide-specific T cell proliferation at the endpoint of the experiment using KLH-peptide/Alum to immunize mice.

For detecting the levels of specific IgM and IgG antibody with ELISA, peptides, S1 protein, or inactivated virus particles were coated onto microplates at 4°C overnight, respectively. And then, 50 μl of serum sample was added and incubated at 37 °C for 1h, followed by incubation with HRP- 

Journal Pre-proof

To analyze the affinity of the antisera, a similar experiment was performed with a modification that the serum samples were added with a mix with different concentrations of NaSCN.

To detect if the peptide was exposed on the surface of VLPs, capture antibody was coated onto the plates, and then VLPs samples were added, followed by using KLH-peptide immunized serum to provide detection antibodies.

Isolated splenocytes were stimulated with corresponding peptide and then analyzed for T cell proliferation. Briefly, a cell proliferation assay was performed following the manufacturer's instructions for the CellTiter 96® AQueous One Solution Cell Proliferation Assay (Promega). Briefly, the isolated splenic lymphocytes were adjusted to 5 × 10 4 cells/ml and maintained in DMEM supplemented with 10% FBS, 100 U penicillin/ml, and 100 μg streptomycin/ml at 37

• C with 5% CO 2 .

Corresponding peptide was added to wells at concentrations of 5 μg/ml. After incubating cells at 37

• C for 48 h, 20 μl of MTS reagent was added to each well. After an additional incubation for 2 h at 37 • C, the optical absorbance at 490 nm was determined for each well.

To evaluate the neutralizing activity of peptides-elicited antibodies against SARS-COV-2 infection, Vero E6 cells (4 × 10 4 /100 μl / well) were seeded in 96-well plates and cultured overnight.

Pre-incubate the 50 μl of immunized mouse serum (diluted in different dilutions with medium) with 50 μl of 100 tissue-culture infectious dose (TCID50) of SARS-COV-2 in medium at 37°C for 1 hour, and then add the mixture to Vero E6 cell. Plates were incubated for 3-5 days at 37 °C in a 5% CO 2 incubator. Cytopathic effect (CPE ) of each well was recorded under microscopes, and the neutralizing titer was calculated by the dilution number of 50% protective condition (33).

The synthetic peptides were coupled to KLH respectively and emulsified with aluminum adjuvant. The mice were immunized subcutaneously three times at two-week intervals (Figure 2A ).

One week after the primary immunization, peptide-specific IgM responses were checked with ELISA.

As shown in Figure 2B , P1, P7, P3, P4, P5 and P6 elicited IgM responses in a descending order, while P2, P8, and P9 didn't show clear responses. The sera were collected at one week after each immunization and analyzed for the kinetics of the anti-peptide IgG responses ( Figure 2C ). In a descending order, P1, P5, P3, P7, P2, P4 and P6 induced clearly IgG responses, while P8 and P9

failed to induce IgG production ( Figure 2D ).

In a parallel experiment, the mice were immunized with KLH-peptides conjugates with complete CFA for primary immunization and IFA for the two boosters, and the immunization procedure was the same as that shown in Figure 2A . As shown in Figure 3A , as compared to using alum as adjuvant, the antibody levels were generally increased, and the responsive variation among mice were reduced. To reflect the potentials of peptide-induced antibodies to recognize native S protein, S1 protein was coated on microplates to replace peptides in ELISA. Antisera against P7, P6, P1, P4, and P3 presented distinct reactivity to S1 protein ( Figure 3B ). Using inactivated virus-immunized rhesus monkey antisera to recognize peptides, there was no specific reaction found in the test ( Figure 3C ). As controls, coated S1 protein and inactivated virus presented clear reactivity to monkey sera. Isolated splenocytes from immunized mice were incubated and stimulated with 9

peptides separately, and cell proliferation was checked. Stimulation with P7 and P6 showed clear cell proliferation as compared to the other peptides, indicating that the two peptides include important T cell epitopes ( Figure 3D ). potential with a neutralizing titer of 128, followed by P2, P4, P6 which showed a titer of 32 ( Figure   4B ). Using antisera produced by using Freund's adjuvants, the neutralizing capability of P6 was significantly elevated to a titer of 256 ( Figure 4C ), most likely due to its distinctly enhanced antibody response.

Further, P2, P3, P4, and P6 were presented respectively on the surface of HBcAg VLPs through gene recombinant, which are named as HBcAg-P2, HBcAg-P3, HBcAg-P4, and HBcAg-P6

respectively. As shown in Figure VLPs; in addition, HBcAg-peptide VLPs have similar behavior to HBcAg VLPs.

The recombinant VLPs were coated on microplate for ELISA. As shown in Figure 6A , HBcAg -P2, P3, P4, and P6 VLPs were clearly recognized by antisera derived from the mice immunized with corresponding KLH-peptide conjugates as compared to HBcAg VLPs, indicating that the peptides were successfully presented on the surface of recombinant VLPs. The sera were collected at one

week after the second and third immunizations and specific IgG responses were detected. All the VLPs induced specific IgG responses, and among them, HBcAg-P3 and HBcAg-P6 induced quite high levels of IgG ( Figure 6B ). Especially, HBcAg-P6 induced antibody level is significantly higher than that induced by KLH-P6.

Further, the affinity of these antibodies to peptides or S protein were examined using ELISA with the addition of increased concentration of NaSCN, which was used to interfere with the binding of antibodies to peptides or S1 protein. As shown in Figure 7A , the antibodies induced by HBcAg-P3 and HBcAg-P6 presented higher affinity to the peptides in comparison with those of HBcAg-P2

and HBcAg-P4. Using S1 protein to replace peptides, HBcAg-P6 induced antiserum showed far better affinity to S1 than the other three antisera ( Figure 7B ). The reactivity of VLPs -elicited antibodies to inactivated virus was further detected in ELISA. Although all the four antisera could react with inactivated virus, HBcAg-P6 serum exhibited better recognition than the other three sera ( Figure 7C ). The neutralizing ability of the antibodies induced by the HBcAg-P6 VLPs was checked with cell neutralization assay, the results showed that HBcAg-P6 serum had stronger ability than the antiserum from Alum-adjuvanted KLH-P6 immunization to suppress SARS-COV-2 infection of Vero-E6 cells ( Figure 7D ).

Peptide-based vaccine strategy holds the following advantages over some other vaccine approaches. Firstly, it can be developed fast without the need for scale culture of a virus strain, and convenient to timely adjust and cope with the challenge of emerging virus mutations by including specific peptides (34); secondly, through rational selection and combination of antigenic peptides, J o u r n a l P r e -p r o o f specific desired immune responses can be induced while ineffective and even detrimental responses will be deleted, and thus in favor of avoiding possible vaccine-associated enhanced disease (VAED) or antibody-dependent enhancement (ADE) of infection and diseases (35, 36) . In addition, peptide vaccine may represent an ideal alternative when pathogens cannot use whole-cell methods to produce vaccines due to severe issues such as causing immunopathogenesis or propagation in vitro are not available. However, peptide vaccines also face great challenges.

Peptides are unstable in vivo and tend to be less immunogenic than protein or virus and thus may fail to induce a strong immune response, however, it can be effectively improved through the application of delicately designed adjuvant and delivery system. Polymer nanoparticles, selfassembling nanofibers, or Fe ++ mediated nanoparticles have been widely used as nanoscale vaccine platforms to boost peptide-specific responses (37) (38) (39) . In addition, recombinant virus-like particles (VLPs) are also an ideal vaccine delivery system (32, 40, 41) . However, the linear B cell epitopes generally induce the antibodies showing weaker binding affinity and correspondingly weaker neutralizing activity as compared to conformational epitopes, which limits the use of linear epitopes as a vaccine antigen (42) . Logically, an antibody targeting to key receptor binding sites will produce a direct and crucial effect on blocking the binding of virus to its receptor and its entry into targeting cells, and thus confer a neutralizing protection. Therefore, an important consideration for peptide-based vaccine is to elicit strong responses of high affinity antibody targeting to key sites.

Based on this basic concept, in this study, we focused on identify antigenic epitopes in RBM of spike protein of SARS-COV-2, which is the interactive interface between S protein and its receptor ACE2 (20) . Predicting antigenic epitopes through a bioinformatics strategy is frequently used. The antigenic peptides mainly predicted by hydrophilia / hydropilicity, secondary structure, surface exposure, and statistical data of identified epitopes (43) . However, the predictive accuracy is unexpectable and may also miss possible effective epitopes. As for SARS-COV-2, some groups have reported their epitope prediction for guiding peptide-based vaccine design (29) , but mostly lack functional verification for using as a vaccine antigen. Another method to analyze B cell epitope of SARS-COV-2 is to screen sets of synthetic peptides using convalescence sera of COVID-19

Journal Pre-proof patients (44) . This method has apparent advantages since the reactivity clearly indicates that the peptide induced specific antibody and thus is definitely an antigenic epitope in virus protein.

However, whether it holds the potential as a vaccine antigen is still need to be further identified;

further, the strategy may neglect some peptides which show poor or even no antigenicity in native proteins and thus induce no antibody production when virus infection, but they locate at key neutralizing sites and hold antigenic potentials if being properly presented. In this study, we synthesized a set of overlapping peptides and conjugated them to KLH. Our concept is actually quite simple, that is, using appropriate adjuvant and delivery system to empower the peptides more antigenicity to boost the responses of immune system, in combination with careful assessment of the production and neutralizing activity of induced specific antibodies, we have chances to find useful neutralizing epitope candidates including those underprivileged in native proteins.

As an early antigenic screening, we chose the commonly used vaccine carrier protein KLH for peptide coupling. The approach provides a powerful carrier effect through stimulating innate immunity and T cell response to ensure that the synthetic peptide effectively induce antibody responses if peptide itself possess antigenicity. By conjugated to carrier KLH and adjuvanted with alum, 7 of 9 RBM peptides in this study successfully induced peptide-specific antibody response.

After testing the neutralizing activity of these antisera with alive virus-based cell neutralizing assay, we found P2, P3, P4, and P6 presented clearly neutralizing activity with P3 showing the strongest effect. Analyzing the responsive titers and neutralizing titers of the antibodies, P6 draw our attention successfully since its antibody titer is significantly lower than the others. Using an antisera derived from a parallel experiment with the stronger adjuvant CFA/IFAs to instead of alum for immunization, we did find that the antibody responses to the peptides were enhanced, especially for P6. Not surprising, P6 antiserum from FAs presented a higher neutralizing activity than that from alum adjuvant, and became even higher than the other peptide sera. Interesting, inactivated virusinduced antiserum in rhesus monkey didn't recognize these synthetic linear peptides. The above results indicated that peptides which show low or even no antigenicity could be empowered to induce a robust specific antibody responses if using appropriate carrier and adjuvant; in addition,

Journal Pre-proof these peptides might provide crucial neutralizing activity. Comparing chemically conjugating the peptides to a carrier protein, recombinant virus-like particles have dominant advantages to deliver peptides since the peptides are highly ordered and organized presented with high copy onto the VLPs, which provides strong stimulation signals to immune systems; besides, 20-30 nm size of VLP facilitates uptake, processing and presentation of antigen by antigen presenting cells (APCs) and migration of antigen into lymph nodes where there are more APCs. By using VLPs, we elicited high titers of specific antibodies against the peptides. Obviously, using VLPs as an antigen delivery platform did help elicit a more robust antibody response than KLH. The antibody titers are not certainly correlated with protective effects especially in the case of peptide-based vaccine. In addition to the location of peptides in native protein and virus, the affinity of antibody is also a key factor. After showing that P6 antiserum could effectively bind to virus particles, we further demonstrated that it had strongest affinity to peptides and S1 protein among all the tested peptideinduced sera, using a brief binding assay with the addition of NaSCN during the incubation of antisera.

In our results, KLH-P2 and KLH-P5 antisera had high peptide-specific antibody titers ( Figure 3A) but weak recognition to S1 protein ( Figure 3B ). We speculated that the difference of antibody binding activity to peptide and S1 protein may attributed to 1) peptides in S1 protein may present some differences on secondary structure comparing with coated free peptides in ELISA due to the restriction of flanking structure elasticity and influences of spatially adjacent amino acid residues; 2) the exposure of the peptides are poor or key antigenic determinants of the peptides may be covered in S1 protein. Similarly, KLH-P1 antiserum was highly reactive towards S1-protein but showed low neutralizing activity. We speculated that it might owe to that ELISA results reflect the number of binding antibodies, while neutralization activity much more depends on the binding strength of antibody to antigen and the location of recognized site.

Taken together, in this study we identified antigenic peptides in RBM of SARS-COV-2 S protein, which hold a potential of eliciting specific antibodies and providing neutralizing protection, and we also showed that using recombinant VLPs as a deliver platform to highlight the antigenicity of the 

Coronavirus Disease (COVID-19) Dashboard

Use of

Pfizer-BioNTech COVID-19 Vaccine in Persons Aged ≥ 16 Years: Recommendations of the Advisory Committee on Immunization Practices -United States

WHO validates Sinovac COVID-19 vaccine for emergency use and issues interim policy recommendations

Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: J o u r n a l P r e -p r o o f two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. The Lancet Infectious Diseases

Efficacy and Safety of a COVID-19 Inactivated Vaccine in Healthcare Professionals in Brazil: The PROFISCOV Study

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Tracking SARS-CoV-2 variants

Vaccine efficacy in mutant SARS-CoV-2 variants

Serum sample neutralisation of BBIBP-CorV and ZF2001 vaccines to SARS-CoV-2 501Y.V2

Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera and monoclonal antibodies

Omicron (B.1.1.529): Infectivity, vaccine breakthrough, and antibody resistance. ArXiv. 2021. 17. Draft landscape of COVID-19 candidate

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Peptide-based synthetic vaccines

Present status and future perspective of peptide-based vaccine therapy for urological cancer

Cancer-Testis Antigen Peptide Vaccine for Cancer Immunotherapy: Progress and Prospects

Immunoinformatics Approach for the Identification and Characterization of T Cell and B Cell Epitopes towards the Peptide-Based Vaccine against SARS-CoV-2

Immunoinformatic Analysis of Tand B-Cell Epitopes for SARS-CoV-2 Vaccine Design. Vaccines (Basel)

A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV

Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients

Recombinant virus-like particles presenting IL-33 successfully modify the tumor microenvironment and facilitate antitumor immunity in a model of breast cancer

Development of an inactivated vaccine candidate for SARS-CoV-2

Peptide Vaccine: Progress and Challenges. Vaccines (Basel)

Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates

Nonglycosylated G-Protein Vaccine Protects against Homologous and Heterologous Respiratory Syncytial Virus (RSV) Challenge, while

Protein Polymer-Based Nanoparticles: Fabrication and Medical Applications

Local mucosal immunization of selfassembled nanofibers elicits robust antitumor effects in an orthotopic model of mouse genital tumors

Self-Assembled Nanofibers Elicit Potent HPV16 E7-Specific Cellular Immunity And Abolish Established TC-1 Graft Tumor

Virus-Like Particles Presenting the FGF-2

Protein or Identified Antigenic Peptides Promoted Antitumor Immune Responses in Mice

Glycan-Modified Virus-like Particles Evoke T Helper Type 1-like Immune Responses

Linear epitope landscape of the SARS

CoV-2 Spike protein constructed from 1,051 COVID-19 patients

Novel recombinant interleukin-13 peptide-based vaccine reduces airway allergic inflammatory responses in mice

Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody

Qiong Long: Validation; Formal analysis; Investigation; Data Curation; Writing -Original; Writing -Review & Editing

Ying Yang: Validation; Formal analysis; Investigation; Writing -Review & Editing; Writing -Review

Mengli Yang: Investigation

Data Curation

Hongmei Bai: Investigation

Wengjia Sun: Investigation

Yanbing Ma: Conceptualization; Methodology; Resources; Supervision